OBJECTIVE: Methamphetamine is one of the most commonly used illicit drugs during pregnancy, highlighting the importance of understanding the risks associated with its use and adverse pregnancy outcomes. We sought to determine the association between methamphetamine use and pregnancy outcomes in a large cohort of US women. STUDY DESIGN: This was a retrospective cohort study of pregnancies in California from 2007 to 2011 using the California birth registry. Subjects were stratified into two groups: methamphetamines use during pregnancy versus no methamphetamine use. We assessed maternal demographics and characteristics in addition to pregnancy outcomes. Differences were analyzed by Pearson's chi-square, t-test, and logisticregression, with a¼0.05.
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RESULTS:
Of 2,393,939 non-anomalous singleton pregnancies 23 to 42 weeks' gestation, 9,423 (0.39%) of women used methamphetamines during pregnancy. Methamphetamine users were more likely to be diagnosed with gestational hypertension or preeclampsia (10.6% vs 5.7%, p<0.001) and had an increased probability of severe maternal morbidity (4.2% vs 1.1%, p<0.001) ( Table 1) . Preterm delivery <37 weeks (29.4% vs 10.6% p<0.001) and neonatal hypoglycemia (1.9% vs 0.8%, p<0.001) were also more common among methamphetamine users. When adjusting for maternal characteristics and other substance use (tobacco, cannabis, and opioids), methamphetamine use was associated with multiple adverse maternal and neonatal outcomes (Figure 1) . CONCLUSION: Among a large cohort of pregnant women, methamphetamine use was associated with an increased odds of severe maternal morbidity, in addition to multiple other adverse maternal and neonatal outcomes. This reinforces the importance of identifying methamphetamine use during pregnancy to mitigate these adverse outcomes.
313 Medication-Assisted Treatment (MAT) in pregnancy: methadone and buprenorphine Cara Staszewski, Kimberly Herrera, Malini D. Persad, Victoria Ly, Diana Garretto, Jay Davis, David J. Garry Stony Brook University Hospital, Stony Brook, NY OBJECTIVE: To compare pregnancy outcomes in Medication-Assisted Treatment (MAT) with methadone or buprenorphine. STUDY DESIGN: A retrospective cohort of women receiving MAT with either methadone or buprenorphine were identified from delivery and newborn records at our tertiary care hospital over a 10-year period. Women were excluded with delivery less than 24 weeks, a multiple gestation, or a known anomalous fetus. Maternal demographics, medications, GA and mode of delivery, birthweight, newborn length of stay, and neonatal abstinence syndrome were extracted from the medical record. The study was IRB approved and 
